Cargando…

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients

Detalles Bibliográficos
Autores principales:	Fonseca, Rodrigo, Arribas, Mariano, Wiedmeier-Nutor, Julia E., Kusne, Yael N., González Vélez, Miguel, Kosiorek, Heidi E., Butterfield, Richard (Duke) J., Kirsch, Ilan R., Mikhael, Joseph R., Stewart, A. Keith, Reeder, Craig, Larsen, Jeremy, Bergsagel, P. Leif, Fonseca, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212911/ https://www.ncbi.nlm.nih.gov/pubmed/37230980 http://dx.doi.org/10.1038/s41408-023-00856-0

Ejemplares similares

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

Effects of Intense Pulsed Light on Tear Film TGF-β and Microbiome in Ocular Rosacea with Dry Eye
por: Sagaser, Samantha, et al.
Publicado: (2021)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

Utility of flow cytometry screening before MRD testing in multiple myeloma
por: Panakkal, Vandana, et al.
Publicado: (2023)

P889: WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT)
por: Askeland, F. B., et al.
Publicado: (2022)

Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
por: Reeder, Craig B., et al.
Publicado: (2009)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier-Nutor, Julia E., et al.
Publicado: (2023)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity
por: Suzuki, Kazuhito, et al.
Publicado: (2021)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy
por: Kaufman, Adrienne, et al.
Publicado: (2021)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
por: Wiedmeier, Julia E., et al.
Publicado: (2021)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
por: Papadimitriou, Konstantinos, et al.
Publicado: (2020)

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
por: Bobin, Arthur, et al.
Publicado: (2020)

Mortality and glycemic control among patients with diabetes mellitus and uterine or ovarian cancer
por: Kusne, Yael N, et al.
Publicado: (2020)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma
por: Kumar, Shaji K., et al.
Publicado: (2018)

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
por: Hussain, Sajjad, et al.
Publicado: (2015)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

P859: ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS
por: Meseguer Martinez, E., et al.
Publicado: (2022)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jrp6afbt7ovqhfpi7co5prgs1g